US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into ...

The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis,” published in the March 2025 issue of Rheumatology by ...

Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains unknown, lacking validated models, biomarkers and effective treatment ...

Frampton announced in 2019 that he was diagnosed with inclusion body myositis (IBM). According to Johns Hopkins Medicine, IBM is a rare condition that affects the muscles. It causes them to weaken ...